Can low omega-3 status and a high omega-6 to omega-3 ratio impair inflammation resolution and HDL-related lipid transport quality?

Dietary polyunsaturated fatty acid (PUFA) profiles profoundly shape systemic inflammatory responses and lipid transport kinetics by altering membrane composition. An elevated omega-6 to omega-3 ratio, alongside low omega-3 status, significantly disrupts active healing pathways and lipoprotein functionality.

Impaired inflammation resolution

• Enzymatic competition: Omega-6 and omega-3 PUFAs compete for the same cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. Under high omega-6 to omega-3 ratios, enzymes preferentially produce pro-inflammatory eicosanoids over anti-inflammatory mediators.
• Suppressed SPM synthesis: This enzymatic bias prevents "lipid mediator class switching" and deprives the body of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) substrates. This reduces the biosynthesis of specialized pro-resolving mediators (SPMs)—resolvins, protectins, and maresins—which are essential for limiting neutrophil infiltration and promoting macrophage-led efferocytosis. Maintaining a ratio of ≤4:1 is associated with restored SPM production.

Dysfunctional HDL lipid transport

• Membrane remodeling: Omega-3 incorporation into HDL phospholipids determines particle fluidity, size, and maturation. A high omega-6 to omega-3 ratio alters the phospholipid micro-environment, compromising reverse cholesterol transport (RCT) dynamics.
• Reduced PON1 and efflux capacity: High omega-6 content in HDL is inversely associated with paraoxonase-1 (PON1) activity. Conversely, omega-3 enrichment upregulates and stabilizes PON1, preserving HDL antioxidant defenses and supporting apolipoprotein A-I (ApoA-I) exchange, which is critical for efficient cholesterol efflux from macrophages.

Bottom line

• A high dietary omega-6 to omega-3 ratio and low omega-3 status impair systemic health by starving biochemical pathways of the EPA/DHA substrates needed to synthesize inflammation-resolving SPMs and by compromising HDL phospholipid structure, which reduces PON1 activity and impairs reverse cholesterol transport.